Fateh Bazerbachi1, Samir Haffar2, Tarek Sawas1, Eric J Vargas1, Ravinder Jeet Kaur1, Zhen Wang3, Larry J Prokop4, M Hassan Murad3, Barham K Abu Dayyeh5. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. 2. Digestive Center for Diagnosis and Treatment, 29 Ayar Street, Damascus, Syrian Arab Republic. 3. Mayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, MN, USA. 4. Department of Library Services, Mayo Clinic, Rochester, MN, USA. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. abudayyeh.barham@mayo.edu.
Abstract
BACKGROUND: Four commercially available intragastric balloons have been used for the management of obesity and underwent randomized controlled trials (RCTs), and we aimed to compare them using a network meta-analysis approach. METHODS: Several databases were queried from inception to May 26, 2017, and we included RCTs enrolling patients treated with Orbera, Heliosphere, ReShape Duo, and Obalon compared with another balloon, sham, or open-label control group. Two investigators independently abstracted data. A random effects frequentist network meta-analysis and relative ranking of agents using surface under the cumulative ranking probabilities were performed. RESULTS: We included 15 trials at low risk of bias (only two were head-to-head). Compared to control groups, the two fluid-filled devices were associated with significant outcome (% total body weight loss) at 6 months: Orbera, 6.72% (95% CI, 5.55, 7.89) and ReShape Duo 4% (95% CI 2.69, 5.31). Only one of the two gas-filled devices was associated with significant outcome at 6 months: Obalon 3.3% (95% CI 2.30, 4.30), and not the second: Heliosphere 6.71% (95% CI - 0.82, 14.23). Fluid-filled devices had the highest likelihood of superiority in achieving the outcome at 6 months (96.8%) and at 12 months (96.6%). The quality of evidence was high for comparisons against control. CONCLUSIONS: Fluid-filled balloons are more likely to produce weight loss compared to gas-filled balloons or lifestyle intervention. However, they may be associated with a higher rate of intolerance and early removal. This information will aid clinicians in device selection and engaging patients in shared decision-making.
BACKGROUND: Four commercially available intragastric balloons have been used for the management of obesity and underwent randomized controlled trials (RCTs), and we aimed to compare them using a network meta-analysis approach. METHODS: Several databases were queried from inception to May 26, 2017, and we included RCTs enrolling patients treated with Orbera, Heliosphere, ReShape Duo, and Obalon compared with another balloon, sham, or open-label control group. Two investigators independently abstracted data. A random effects frequentist network meta-analysis and relative ranking of agents using surface under the cumulative ranking probabilities were performed. RESULTS: We included 15 trials at low risk of bias (only two were head-to-head). Compared to control groups, the two fluid-filled devices were associated with significant outcome (% total body weight loss) at 6 months: Orbera, 6.72% (95% CI, 5.55, 7.89) and ReShape Duo 4% (95% CI 2.69, 5.31). Only one of the two gas-filled devices was associated with significant outcome at 6 months: Obalon 3.3% (95% CI 2.30, 4.30), and not the second: Heliosphere 6.71% (95% CI - 0.82, 14.23). Fluid-filled devices had the highest likelihood of superiority in achieving the outcome at 6 months (96.8%) and at 12 months (96.6%). The quality of evidence was high for comparisons against control. CONCLUSIONS: Fluid-filled balloons are more likely to produce weight loss compared to gas-filled balloons or lifestyle intervention. However, they may be associated with a higher rate of intolerance and early removal. This information will aid clinicians in device selection and engaging patients in shared decision-making.
Entities:
Keywords:
Bariatric endoscopic therapies; Therapeutic endoscopy; Weight loss
Authors: Jaime Ponce; George Woodman; James Swain; Erik Wilson; Wayne English; Sayeed Ikramuddin; Eric Bour; Steven Edmundowicz; Brad Snyder; Flavia Soto; Shelby Sullivan; Richard Holcomb; John Lehmann Journal: Surg Obes Relat Dis Date: 2014-12-16 Impact factor: 4.734
Authors: Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427
Authors: R B Hogan; J H Johnston; B W Long; J Q Sones; L A Hinton; J Bunge; S A Corrigan Journal: Gastrointest Endosc Date: 1989 Sep-Oct Impact factor: 9.427
Authors: Eric J Vargas; Fateh Bazerbachi; Andrew C Storm; Monika Rizk; Andres Acosta; Karen Grothe; Matt M Clark; Manpreet S Mundi; Carl M Pesta; Ahmad Bali; Eric Ibegbu; Rachel L Moore; Vivek Kumbhari; Trace Curry; Reem Z Sharaiha; Barham K Abu Dayyeh Journal: Obes Surg Date: 2019-12 Impact factor: 4.129
Authors: Eric J Vargas; Fateh Bazerbachi; Gerardo Calderon; Larry J Prokop; Victoria Gomez; M Hassan Murad; Andres Acosta; Michael Camilleri; Barham K Abu Dayyeh Journal: Clin Gastroenterol Hepatol Date: 2019-04-04 Impact factor: 11.382
Authors: Shailendra Singh; Diogo Turiani Hourneaux de Moura; Ahmad Khan; Mohammad Bilal; Monica Chowdhry; Michele B Ryan; Ahmad Najdat Bazarbashi; Christopher C Thompson Journal: Obes Surg Date: 2020-08 Impact factor: 4.129
Authors: Fateh Bazerbachi; Eric J Vargas; Monika Rizk; Daniel B Maselli; Taofic Mounajjed; Sudhakar K Venkatesh; Kymberly D Watt; John D Port; Rita Basu; Andres Acosta; Ibrahim Hanouneh; Naveen Gara; Meera Shah; Manpreet Mundi; Matthew Clark; Karen Grothe; Andrew C Storm; Michael J Levy; Barham K Abu Dayyeh Journal: Clin Gastroenterol Hepatol Date: 2020-04-30 Impact factor: 11.382
Authors: Andrea Telese; Vinay Sehgal; Cormac G Magee; S Naik; S A Alqahtani; L B Lovat; Rehan J Haidry Journal: Clin Transl Gastroenterol Date: 2021-06-18 Impact factor: 4.488
Authors: Fadi Hawa; Eric J Vargas; Andres Acosta; Alison McRae; Fateh Bazerbachi; Barham K Abu Dayyeh Journal: BMC Gastroenterol Date: 2021-07-12 Impact factor: 3.067